RxDoctor Payments DataLook up a doctor →

Sherif Haraway, MD

Neurology · North Las Vegas, NVNPI 1104029164

Payments from drug & device makers

$10,118in general payments, 2019–2025

Across 350 payments — averaging $28.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Biotronik NRO, Inc.$1K
  • AbbVie$852
  • Novartis$843
  • Boston Scientific$723
  • Biogen$544
  • plus $4K from 42 others

What the payments were for

  • Travel & lodging$2,35423%
  • Food & beverage$7,53674%
  • Education$2282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,118 in reported general payments places this provider in the 70th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$220,571
Medicare patients
299
Services billed
2,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4625$139,328
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5025$91,528
BotoxOnabotulinumtoxina27$32,454
Nurtec OdtRimegepant Sulfate11$18,270
NamzaricMemantine Hcl/Donepezil Hcl17$11,195
OxycontinOxycodone Hcl15$10,738
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen109$2,935
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen73$2,713
Oxycodone Hcl87$1,261
Galantamine Hbr18$911
Memantine Hcl81$905
Primidone59$901
Donepezil Hcl111$599
Gabapentin59$557
Pregabalin30$536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Namzaric$852$43,64944 claims
PfizerNurtec Odt$189$18,27011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 145 neurology providers in Nevada.

Other neurology in North Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →